https://orcid.org/0000-0001-5038-6210
References
- Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps. J Am Coll Cardiol. 2020;75(5):539–555. doi:10.1016/j.jacc.2019.11.046
- Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT. Dysglycemia-based chronic disease: an American association of clinical endocrinologists position statement. Endocr Pract. 2018;24(11):995–1011. doi:10.4158/PS-2018-0139
- Kalra S, Unnikrishnan AG, Baruah MP, Sahay R, Bantwal G. Metabolic and energy imbalance in dysglycemia-based chronic disease. Diabetes Metab Syndr Obes. 2021;14:165–184. doi:10.2147/DMSO.S286888
- Iyengar SS, Narasingan SN, Gandhi P, et al. Risk factors, comorbiditiEs and atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study. J Fam Med Prim Care. 2020;9(8):4156–4164. doi:10.4103/jfmpc.jfmpc_546_20
- Gupta P, Singh K, Shivashankar R, et al. Healthcare utilisation and expenditure patterns for cardio-metabolic diseases in South Asian cities: the CARRS Study. BMJ Open. 2020;10(9):e036317. doi:10.1136/bmjopen-2019-036317
- Gonzalez-Rivas JP, Mechanick JI, Infante-Garcia MM, et al. Prevalence of Dysglycemia-Based Chronic Disease (DBCD) in European population: a new paradigm to address diabetes burden. the KARDIOVIZE study. Endocr Pract. 2020. doi:10.1016/j.eprac.2020.10.003
- Cioffi F, Zambad SP, Chhipa L, et al. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. FASEB J. 2010;24(9):3451–3461. doi:10.1096/fj.10-157115
- Silvestri E, Glinni D, Cioffi F, et al. Metabolic effects of the iodothyronine functional analogue TRC150094 on the liver and skeletal muscle of high-fat diet fed overweight rats: an integrated proteomic study. Mol Biosyst. 2012;8(7):1987–2000. doi:10.1039/c2mb25055a
- Zambad SP, Munshi S, Dubey A, et al. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats. Diabetes Metab Syndr Obes. 2011;4:5–16. doi:10.2147/DMSOTT.S15323
- Joshi D, Jamadarkhana P, Kumbhare S, et al. Safety, tolerability, and pharmacokinetics of a novel mitochondrial modulator, TRC150094, in overweight and obese subjects: a randomized phase-I clinical trial. Front Pharmacol. 2021;12:2465. doi:10.3389/fphar.2021.729424
- van der Valk F, Hassing C, Visser M, et al. The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. PLoS One. 2014;9(2):e86890. doi:10.1371/journal.pone.0086890
- Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61. doi:10.1161/HYPERTENSIONAHA.107.100727
- Vial G, Detaille D, Guigas B. Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol. 2019;10. doi:10.3389/fendo.2019.00294
- Detaille D, Vial G, Borel A-L, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016;2(1):15072. doi:10.1038/cddiscovery.2015.72